You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》摩通予君實生物(01877.HK)目標價68元 指業務前景鞏固
阿思達克 09-21 14:22
摩根大通發表報告指,君實生物(01877.HK)繼續在臨床、監管及業務發展上有穩健的進展,旗下PD-1獲FDA突破性療法認定,估計公司將繼續擴張海外市場足跡。另外禮來公司(LLY.US)早前公布了新冠病毒中獲取了中和抗體驗證數據,而君實亦正透過與微境生物就四款抗腫瘤小分子藥物達成合作擴闊產品線。該行重申予君實生物「增持」評級,目標價68元。

該行指出,君實生物(旗下PD-1獲FDA突破性療法認定,是中國首次,認為為國際市場開啟了大門,相信有助大幅加快藥物開發及潛在於美國及中國以外市場獲批。考慮到現時數據正面,加上相關需求未被滿足,相信最快可在2021年尾獲得FDA的批准,並料對海外市場潛在合作有幫助,為公司帶來更多上行空間。(el/w) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account